We recently published a list of 10 Best Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are going ...
We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a ...
We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to ...
In a report released today, Jonathan Woo from Phillip Securities maintained a Buy rating on Akero Therapeutics (AKRO – Research Report), with a ...
In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against other best performing pharma stocks so far in 2025. On February 20, Jared Holz ...
Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) has been given an average recommendation of “Buy” by the nine analysts that are covering the stock, Marketbeat Ratings reports.
AKRO opened at $54.08 on Friday. Akero Therapeutics has a 12-month low of $15.32 and a 12-month high of $58.40. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to ...
Investing.com - Akero Therapeutics (NASDAQ: AKRO) reported first quarter EPS of $-0.55, $0.12 better than the analyst estimate of $-0.67. Revenue for the quarter came in at $0.00 ...
Fintel reports that on January 30, 2025, B of A Securities upgraded their outlook for Akero Therapeutics (NasdaqGS:AKRO) from Neutral to Buy. Analyst Price Forecast Suggests 23.34% Upside As of ...
Rolph Timothy, the Chief Scientific Officer of Akero Therapeutics Inc . (NASDAQ:AKRO), recently executed a notable share sale, as per the latest SEC filing. The timing is particularly interesting ...